The major goal of the Dominantly Inherited Alzheimer Network Neuropathology Core (DIAN-NPC) is to provide a neuropathological diagnosis on all participants in DIAN and family members who come to autopsy, to exchange data with the DIAN Coordinating Center, and to provide diagnostic reports and tissues to collaborating sites. The DIAN-NPC provides the

Public Health Relevance

Although there have been tremendous advances in the development of biomarkers of Alzheimers disease, there remains no reliable method for showing the earliest pathological changes in the brain or the presence of additional pathology which may contribute to the progression and symptoms of the disease. The Neuropathology Core of DIAN is essential to provide a neuropathological diagnosis on all participants and family members who come to autopsy - it is the gold standard against which all biomarker and clinical assessments are judged. The importance of the Neuropathology Core is demonstrated by the observation that in DIAN participants there often is additional Lewy body disease that was not detected by any biomarker, clinical or other assessment and likely contributes to the rate and nature of the cognitive and motor impairment in vulnerable individuals.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Multi-Year Funded Research Project Cooperative Agreement (UF1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Oxtoby, Neil P; Young, Alexandra L; Cash, David M et al. (2018) Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain 141:1529-1544
Chhatwal, Jasmeer P; Schultz, Aaron P; Johnson, Keith A et al. (2018) Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain 141:1486-1500
Franzmeier, Nicolai; Düzel, Emrah; Jessen, Frank et al. (2018) Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain 141:1186-1200
Hsu, Simon; Gordon, Brian A; Hornbeck, Russ et al. (2018) Discovery and validation of autosomal dominant Alzheimer's disease mutations. Alzheimers Res Ther 10:67
Wang, Guoqiao; Berry, Scott; Xiong, Chengjie et al. (2018) A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med 37:3047-3055
Gordon, Brian A; Blazey, Tyler M; Su, Yi et al. (2018) Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol 17:241-250
Stout, Sarah H; Babulal, Ganesh M; Ma, Chunyu et al. (2018) Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimers Dement 14:610-616
Villeneuve, Sylvia; Vogel, Jacob W; Gonneaud, Julie et al. (2018) Proximity to Parental Symptom Onset and Amyloid-? Burden in Sporadic Alzheimer Disease. JAMA Neurol 75:608-619
Lim, Yen Ying; Hassenstab, Jason; Goate, Alison et al. (2018) Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Ann Neurol 84:424-435
Suárez-Calvet, Marc; Capell, Anja; Araque Caballero, Miguel Ángel et al. (2018) CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. EMBO Mol Med 10:

Showing the most recent 10 out of 59 publications